[1] Mahapatra S, Reddy S, Duggal S, et al.Community-acquired methicillin-resistant Staphylococcus aureus pneumonia[J]. Cureus, 2024, 16(10): e72166.
[2] Gilmore CM, Vargus A, Lee GC, et al.Guideline-concordant antibiotic prescribing for community-acquired bacterial pneumonia (CABP) due to drug-resistant pathogens in the All of US Database[J]. J Clin Transl Sci, 2025, 9(1): e214.
[3] Frazee BW, Singh A, Labreche M, et al.Methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa community acquired pneumonia: Prevalence and locally derived risk factors in a single hospital system[J]. J Am Coll Emerg Physicians Open, 2023, 4(6): e13061.
[4] Li Y, Tang Y, Qiao Z, et al.Prevalence and molecular characteristics of community-associated methicillin-resistant Staphylococcus aureus in the respiratory tracts of Chinese adults with community-acquired pneumonia[J]. J Infect Public Health, 2023, 16(5): 713-718.
[5] 汤鹤, 蒋婷婷, 郭欣, 等. 保定地区社区获得性肺炎儿童金黄色葡萄球菌耐药性分析[J]. 华南预防医学, 2024, 50(7): 675-678.
[6] Tran KQ, Nguyen TTD, Pham VH, et al.Pathogenic role and antibiotic resistance of methicillin-resistant Staphylococcus aureus (MRSA) strains causing severe community-acquired pneumonia in Vietnamese children[J]. Adv Respir Med, 2023, 91(2): 135-145.
[7] 中国医师协会急诊医师分会, 中国急诊专科医联体, 北京急诊医学学会. 急诊成人社区获得性肺炎临床实践指南(2024年版)[J]. 中华急诊医学杂志, 2025, 34(3): 300-317.
[8] Metlay JP, Waterer GW, Long AC, et al.Diagnosis and treatment of adults with community-acquired pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America[J]. Am J Respir Crit Care Med, 2019, 200(7): e45-e67.
[9] 尚红, 王毓三, 申子瑜. 全国临床检验操作规程[M]. 4版. 北京: 人民卫生出版社, 2015: 220-221.
[10] CLSI. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. 3rd ed. CLSI guideline M45[S]. Wayne, PA: Clinical and Laboratory Standards Institute, 2016: 56-58.
[11] Magiorakos AP, Srinivasan A, Carey RB, et al.Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance[J]. Clin Microbiol Infect, 2012, 18(3): 268-281.
[12] Alsolami A, Alghasab NS, Alharbi MSM, et al.Community-acquired methicillin-resistant Staphylococcus aureus in hospitals: Age-specificity and potential zoonotic-zooanthroponotic transmission dynamics[J]. Diagnostics (Basel), 2023, 13(12): 2089.
[13] Nakaminami H.Molecular epidemiological features of methicillin-resistant Staphylococcus aureus in Japan[J]. Biol Pharm Bull, 2025, 48(3): 196-204.
[14] Self WH, Wunderink RG, Williams DJ, et al.Staphylococcus aureus community-acquired pneumonia: Prevalence, clinical characteristics, and outcomes[J]. Clin Infect Dis, 2016, 63(3): 300-309.
[15] Awashima M, Kichikawa Y, Suzuki K, et al.Necrotizing pneumonia caused by community-acquired methicillin-resistant Staphylococcus aureus following influenza[J]. JMA J, 2025, 8(3): 988-989.
[16] Campbell S, Smith S, Hanson J.Lincosamide monotherapy treatment of methicillin-resistant Staphylococcus aureus pneumonia in tropical Australia: A case series[J]. Eur J Clin Microbiol Infect Dis, 2024, 43(6): 1247-1250.
[17] He L, Wang J, Ning Y, et al.Severe pneumonia combined with septic shock caused by community-acquired methicillin-resistant Staphylococcus aureus treated with veno-venous ECMO: A case report[J]. Medicine (Baltimore), 2025, 104(13): e41627.
[18] Whitfield PL, Wendler K, Gabor R, et al.Investigating risk factors for methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in community acquired pneumonia: A model for using only electronic data capture[J]. Pneumonia (Nathan), 2025, 17(1): 32.
[19] Xu G, Liu X, Wang J, et al.Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with Staphylococcus aureus by pharmacokinetic/pharmacodynamic analysis[J]. J Chemother, 2024, 36(8): 709-716.
[20] Shimada S, Yamaguchi T, Mikoshiba S, et al.Relapsing bronchopneumonia due to community-associated methicillin-resistant Staphylococcus aureus: A case report[J]. BMC Infect Dis, 2024, 24(1): 374.
[21] Rallis D, Atzemoglou N, Kapetaniou K, et al.Molecular epidemiology clinical manifestations, decolonization strategies, and treatment options of methicillin-resistant Staphylococcus aureus infection in neonates[J]. Pathogens, 2025, 14(2): 155.
[22] Koga S, Takazono T, Kido T, et al.Evaluation of the effectiveness and use of anti-methicillin-resistant Staphylococcus aureus agents for aspiration pneumonia in older patients using a nationwide Japanese administrative database[J]. Microorganisms, 2023, 11(8): 1905.
[23] Covington EW, Rufe A.Identification of risk factors for multidrug-resistant organisms in community-acquired bacterial pneumonia at a community hospital[J]. J Pharm Pract, 2023, 36(2): 303-308.
[24] Sader HS, Smart JI, Mendes RE, et al.Ceftobiprole activity against multidrug-resistant Staphylococcus aureus clinical isolates collected in the United States from 2016 through 2022[J]. Antimicrob Agents Chemother, 2025, 69(2): e0140224.
[25] Doan K, Smoke S.Antibiotic de-escalation in pneumonia with pharmacist education and ordering of methicillin-resistant Staphylococcus aureus nasal swabs[J]. Eur J Hosp Pharm, 2024, 31(4): 327-331.
[26] Gasoyan H, Deshpande A, Imrey PB, et al.Potential implications of using locally validated risk factors for drug-resistant pathogens in patients with community-acquired pneumonia in US hospitals: A cross-sectional study[J]. Clin Infect Dis, 2024, 79(5): 1277-1282.
[27] Freiberg JA, Siemann JK, Qian ET, et al.Swab Testing to Optimize Pneumonia Treatment with Empiric Vancomycin (STOP-Vanc): Study protocol for a randomized controlled trial[J]. Trials, 2024, 25(1): 854.
[28] 郑艳冰, 崔邵彬, 沙蕾. 耐甲氧西林金黄色葡萄球菌耐药基因及消毒剂耐药相关基因研究[J]. 中国病原生物学杂志, 2024, 19(12): 1437-1441. |
